Development and Evaluation of a Patient-Reported Outcome (PRO) Scale for Breast Cancer

Jun Zhang¹,²*, Yu-Feng Yao¹*, Xiao-Ming Zha³, Li-Qun Pan⁴, Wei-He Bian⁴, Jin Hai Tang¹*

Abstract

**Background:** This study was guided by principles of the theoretical system of evidence-based medicine. In particular, when searching for evidence of breast cancer, a measuring scale is an instrument for evaluating curative effects in accordance with the laws and characteristics of medicine and exploring the establishment of a system for medically assessing curative effects. At present, there exist few tools for evaluating curative effects. Patient-reported outcomes (PROs) refer to outcomes directly reported by patients (without input or explanations from doctors or other intermediaries) with respect to all aspects of their health. Data obtained from PROs provide evidence of treatment effects. **Materials and Methods:** In accordance with the tenets of theoretical medicine and ancient medical theory regarding breast cancer, principles for developing a PRO scale were established, and a theoretical model was developed and a literature review was performed, items from this pool were combined and split, and an initial scale was constructed. After a pilot survey and additional modifications, a pre-questionnaire scale was formed and used in a field investigation. After the application of statistical methods, the item pool was used to create a formal scale. The reliability, validity and feasibility of this formal scale were then assessed. **Results:** In a clinical investigation, 479 responses were recovered, with an acceptance rate of 95%. A combination of various methods was employed, and the items that were selected by all methods or more than half of the methods were employed in the questionnaire. In these cases, the screening methods were combined with certain features of the item, A total of four domains and 38 items were reserved. The reliability analysis indicated that the PRO scale was relatively reliable. **Conclusions:** Scientific assessment proved that the proposed scale exhibited good reliability and validity. This scale was readily accepted and could be used to assess the curative effects of medical therapy. However, given the limited scope of this investigation, the capacity for adapting this scale to incorporate other theories could not be determined.

**Keywords:** PRO scale - breast cancer - evaluation of clinical curative effect

Introduction

Patient-reported outcomes (PROs) comprise a recently proposed evaluation system of therapeutic efficacy that is based on the subjective feelings of patients. A PRO directly reflects patients’ perspectives on various aspects of their health statuses Data obtained by PRO measurements provide evidence for therapeutic efficacy from the perspectives of patient. PRO includes the functional status or objective symptom indices and health-related quality of life. PRO also includes a patient’s satisfaction towards treatment. PRO equally emphasizes the quality-of-life index, the objective symptom index and the non-entity index. Using this knowledge as a guide and modern mathematical statistics as a tool, this study preliminarily established a PRO scale for evaluating breast cancer after surgery (Zhao et al., 2005; Cella et al., 2007; FDA., 2007; Pusic et al., 2009; Arbuckle et al., 2010; Pusic et al., 2013)

The molecular typing-based, individualized precision therapy for breast cancer warrants a good survival rate for breast cancer. A large number of breast cancer patients achieve postoperative long-term survival or manage to survive in the presence of tumours. However, the vast majority of patients experience a variety of health, psychological and behavioural problems related to the disease. Patients suffer not only the general psychological burden of malignant tumours but also the immense psychological impact caused by loss of a breast. The inclusion of PROs in the evaluation of clinical treatment not only compensates for the current lack of indices for evaluating the clinical efficacy of breast cancer treatment but also allows a patient’s condition to be assessed more
accurately than would be possible with universally applicable scales without PROs. (Pusic et al., 2009; Kanatas et al., 2012; Ohsum et al., 2013; Pusic et al., 2013)

Internationally, the quality-of-life scales that are extensively employed for breast cancer have served an important role in guiding our research. This study represents a bold attempt and innovation. Application of the PRO scale in the evaluation of the clinical efficacy of individualized breast cancer therapy is the direction of our research.

**Materials and Methods**

**Generation of primary questionnaire and implementation of clinical survey**

Using the established method of formulating PRO scale as reference, a group composed of breast cancer patients, medical experts and statistical experts was set up, and an envisioned conceptual structural model of a breast cancer-specific PRO scale was established. The model had a five-dimensional structure that consisted of five domains, including physiology, psychology, independence, social relations and the environment.

**Selection of items of the PRO scale**

The methods that were employed to coarsely screen the items included item difficulty analysis and response analysis. The items were re-screened using the following methods: Dispersion tendency analysis and stepwise regression analysis. In the pre-survey, the total score given by patients to their quality of life represents the total situation of the quality of life of patients. Factor analysis and cluster analysis were used to select items based on representativeness. Discriminant analysis - this method primarily selects items from the aspect of distinguishability. Cronbach’s coefficient - this method primarily selects items from the aspect of internal consistency. In this study, the items were classified and examined based on the theoretical structure that was used to design the scale.

**Scientific assessment of the PRO scale**

A scientific assessment of the feasibility, reliability and validity of the PRO scale was conducted. The scientific assessment was completed using the SPSS 15 statistical software package. During the assessment of the structural validity of the scale, the confirmatory factor analysis, the

| Table 1. The Preliminary Version of the Breast Cancer-Specific PRO Questionnaire |
| --- | --- | --- |
| 1. Pain at surgical site | 21. Nausea and heartburn | 41. Dependence on drugs |
| 2. Discomfort and numbness at surgery site | 22. Dryness and bitterness in the mouth | 42. Adoption of anticancer diet |
| 3. Skin itching and dryness in surgical area | 23. Abdominal bloating and pain | 43. Impact of disease on daily life |
| 4. Upper arm movement disorder on the side of surgery | 24. Constipation | 44. Impact of disease on marriage |
| 5. Numbness and pain in the upper arm on the side of surgery | 25. Diarrhea | 45. Impact of falling ill at work |
| 6. Upper arm swelling on the side of surgery | 26. Hair loss | 46. Living an energetic life |
| 7. Distension and pain in contralateral breast | 27. Hot flushes and sweats | 47. Confidence to overcome disease |
| 8. Lump in contralateral breast | 28. Increased sensitivity to cold | 48. Support from friends and family |
| 9. Lump in armpit | 29. Insomnia | 49. Closeness to spouse |
| 10. Menoxenia | 30. Sad and negative feelings | 50. Degree of satisfaction with sexual life |
| 11. Abnormal vaginal discharge | 31. Bad mood | 51. Degree of satisfaction with transportation to hospital |
| 12. Pain in the joints of the extremities | 32. Easily angers and loses temper | 52. Quality of medical service |
| 13. Dizziness and tinnitus | 33. Easily experiences irritability and anxiety | 53. Degree of satisfaction with therapeutic efficacy |
| 14. Soreness and weakness in the waist | 34. Frequently feels nervous due to the disease | 54 Degree of satisfaction with the attending physician |
| 15. Dry eyes | 35. View of personal illness | 55. Quality of life |
| 16. Heart palpitations | 36. Side effects of treatment |  |
Development and Evaluation of a Patient-Reported Outcome (PRO) Scale for Breast Cancer

The affiliate software of SPSS 15.0-AMOS 7 was employed. The feasibility assessment included the clinical usage of the breast cancer-specific PRO scale and the time required to complete the scale. The reliability assessment adopted two common methods: Cronbach’s α coefficient and split-half reliability. The validity of the PRO scale was primarily evaluated from three aspects: content, structure and distinguishability. Assessments of construct validity included an exploratory factor analysis and a confirmatory factor analysis (Anthoine et al., 2014; Fiscella et al., 2011; Luquiens et al., 2015; Mills et al., 2010; McAllister et al., 2011).

Results

Generation of the preliminary version of the PRO questionnaire

Patients who satisfied the diagnostic criteria for breast cancer, already underwent surgery, were capable of expressing their opinions and had no mental illness were included. The patients were interviewed from different aspects and appropriately guided. The information was collected and summarized into items. A clinical survey was conducted using the preliminary questionnaire in the breast surgery clinics of three major hospitals. A total of 200 patients were interviewed. A total of 67 questionnaire items was generated; this number was revised by breast surgery experts. After these revisions, 55 items were included in the preliminary version of the PRO scale.

| Items | Dispersion tendency | Stepwise regression | Factor analysis | Cluster analysis | Discriminant analysis | Cronbach’s coefficient |
|-------|---------------------|---------------------|----------------|-----------------|----------------------|------------------------|
| 1. Pain at the surgical site | # | # | # | # | # | * |
| 2. Discomfort and numbness at the surgical site | # | # | # | # | # | * |
| 3. Skin itching and dryness in the surgical area | # | # | # | # | # | * |
| 4. Upper arm movement disorder on the ipsilateral side | # | # | # | # | # | * |
| 5. Numbness and pain in the upper arm on the ipsilateral side | # | # | # | # | # | * |
| 6. Upper arm swelling on the ipsilateral side | # | # | # | # | # | * |
| 7. Distension and pain in the contralateral breast | # | # | # | # | # | * |
| 8. Lump in the contralateral breast | # | # | # | # | # | * |
| 9. Lump in an armpit | # | # | # | # | # | * |
| 10. Menoxenia | # | # | # | # | # | * |
| 11. Abnormal vaginal discharge | # | # | # | # | # | * |
| 12. Pain in the joints of the extremities | # | # | # | # | # | * |
| 13. Dizziness and tinnitus | # | # | # | # | # | * |
| 14. Soreness and weakness in the waist | # | # | # | # | # | * |
| 15. Dry eyes | # | # | # | # | # | * |
| 16. Heart palpitations | # | # | # | # | # | * |
| 17. Chest tightness and pain | # | # | # | # | # | * |
| 18. Shortness of breath | # | # | # | # | # | * |
| 19. Cough and expectoration | # | # | # | # | # | * |
| 20. Decreased appetite | # | # | # | # | # | * |

Table 2. General Information About the Samples

| Age | Number | Percentage |
|-----|--------|------------|
| 20<n≤35 | 24 | 5 |
| 35<n≤50 | 189 | 39.5 |
| 50<n≤70 | 243 | 50.7 |
| n>70 | 23 | 4.8 |

| Marrie | Number | Percentage |
|-------|--------|------------|
| Married | 357 | 74.5 |
| Unmarried | 122 | 25.5 |

| Breastfeeding | Number | Percentage |
|---------------|--------|------------|
| Already | 324 | 67.6 |
| No | 155 | 32.4 |

| Economic conditions | Number | Percentage |
|--------------------|--------|------------|
| Very good | 25 | 5.2 |
| Good | 107 | 22.3 |
| General | 302 | 63 |
| Poor | 45 | 9.4 |

| Course of disease | Number | Percentage |
|------------------|--------|------------|
| ≤1 year | 139 | 29 |
| 1<n≤2 | 104 | 21.7 |
| 2<n≤3 | 158 | 33 |
| 3<n≤5 | 78 | 16.3 |

Table 3. The Results of Various Screening Approaches for Assessing the Breast Cancer-Specific PRO Questionnaire
These items of the proposed scale were divided into the following five domains: physiology, psychology, personal life, social relations and social environment.

**General information about the samples**

A total of 479 female outpatients were examined. The majority of patients (51.6%) ranged between 35 and 50 years of age. The distribution of the course of disease

| Items                                                                 | Dispersion tendency | Stepwise regression | Factor analysis | Cluster analysis | Discriminant analysis | Cronbach's coefficient | Selected items |
|----------------------------------------------------------------------|---------------------|---------------------|-----------------|------------------|-----------------------|------------------------|----------------|
| 21. Nausea and heartburn                                             | #                   | #                   | #               | #                | #                     | #                      |                |
| 22. Dryness and bitterness in the mouth                              |                     |                     | #               | #                |                       |                        |                |
| 23. Abdominal bloating and pain                                      | #                   | #                   | #               | #                | #                     | #                      |                |
| 24. Constipation                                                      | #                   | #                   | #               |                  |                       |                        |                |
| 25. Diarrhoea                                                         | #                   | #                   | #               |                  |                       |                        |                |
| 26. Hair loss                                                         | #                   | #                   | #               |                  |                       |                        |                |
| 27. Hot flushes and sweats                                           | #                   | #                   | #               | #                | #                     | #                      |                |
| 28. Increased sensitivity to cold                                     |                     |                     | #               | #                |                       |                        |                |
| 29. Insomnia                                                         | #                   | #                   | #               |                  |                       |                        |                |
| 30. Sad and negative feelings                                        | #                   | #                   | #               |                  |                       |                        |                |
| 31. Bad mood                                                         | #                   | #                   | #               |                  |                       |                        |                |
| 32. Easily becomes angry and loses temper                            | #                   | #                   | #               |                  |                       |                        |                |
| 33. Easily experiences irritability and anxiety                       | #                   | #                   | #               |                  |                       |                        |                |
| 34. Frequently feels nervous due to the disease                      | #                   | #                   | #               |                  |                       |                        |                |
| 35. View of personal illness                                         | #                   | #                   | #               |                  |                       |                        |                |
| 36. Side effects of treatment                                        | #                   | #                   | #               |                  |                       |                        |                |
| 37 Fear of metastasis                                                | #                   | #                   | #               |                  |                       |                        |                |
| 38. Fear of disease progression                                      | #                   | #                   | #               |                  |                       |                        |                |
| 39. Fear of infection                                                 | #                   | #                   | #               |                  |                       |                        |                |
| 40 Fear of long-lasting discomfort                                    | #                   | #                   | #               |                  |                       |                        |                |
| 41. Dependence on drugs                                              | #                   | #                   | #               |                  |                       |                        |                |
| 42. Adoption of an anticancer diet                                   | #                   | #                   | #               |                  |                       |                        |                |
| 43. Impact of disease on daily life                                  | #                   | #                   | #               |                  |                       |                        |                |
| 44. Impact of disease on marriage                                    | #                   | #                   | #               |                  |                       |                        |                |
| 45. Impact of falling ill at work                                    | #                   | #                   | #               |                  |                       |                        |                |
| 46. Living an energetic life                                         | #                   | #                   | #               |                  |                       |                        |                |
| 47. Confidence to overcome disease                                   | #                   | #                   | #               |                  |                       |                        |                |
| 48. Support from friends and family                                  | #                   | #                   | #               |                  |                       |                        |                |
| 49. Closeness to spouse                                              | #                   | #                   | #               |                  |                       |                        |                |
| 50. Degree of satisfaction with sexual life                          | #                   | #                   | #               |                  |                       |                        |                |
| 51. Degree of satisfaction with transportation to the hospital       | #                   | #                   | #               |                  |                       |                        |                |
| 52. Quality of medical service                                       | #                   | #                   | #               |                  |                       |                        |                |
| 53. Degree of satisfaction with therapeutic efficacy                 | #                   | #                   | #               |                  |                       |                        |                |
| 54 Degree of satisfaction with the attending physician               | #                   | #                   | #               |                  |                       |                        |                |
| 55. Quality of life                                                  | #                   | #                   | #               |                  |                       |                        |                |
Development and Evaluation of a Patient-Reported Outcome (PRO) Scale for Breast Cancer

Results of various screening methods and the final structure of the breast cancer-specific PRO scale

In the process of reviewing and screening the items, the items selected by different methods were not completely identical. Therefore, a combination of various methods was employed, and the items that were selected by all methods or more than half of the methods were employed in the questionnaire. Some items cannot be determined by these methods. In these cases, the screening methods were combined with certain features of the item, such as professional knowledge and operability, and scale reliability and validity assessment to determine whether the item should be included or excluded. A total of four domains and 37 items were reserved. In addition, a self-evaluation item regarding the quality of life was added. Therefore, a total of 38 items were included in the questionnaire (Tables 3 and 4). The structure of the final version of the breast cancer-specific PRO scale is presented below (Table 5).

Based on the structure, the score of a domain/aspect of the scale was the cumulative score of the items that belonged to the domain/aspect. A grading system was set up to classify the items in the PRO scale into five grades. The five grades had scores of one, two, three, four or five points, where one point denoted the worst grade and five points denoted the best grade. High scores indicate a high quality of life, whereas low scores indicate a low quality of life. However, various domains contained different numbers of items, which hindered the comparison between the scores of the domains. Therefore, the average score of each domain was calculated, which enabled a comparison between the domains.

Assessment of the reliability and validity of the PRO scale
The results of the reliability assessment showed that the breast cancer-specific PRO scale exhibited good reliability. The results also indicated that the related syndrome elements only experienced a low degree of disturbance in the process of utilizing the scales to summarize the pathogenesis of breast cancer, which may clarify the main symptom of the clinical syndrome. The validity results showed that the first factor included items that reflected information in four domains: psychology, independence, social relationships, and social environment. Therefore, we believe that the PRO scale possessed not only construct validity but also content validity. Therefore, the study findings indicated that the current PRO scale exhibited satisfactory discriminant validity.

Discussion

PRO measures not only evaluate the efficacy of a stage of treatment but also serve a certain guiding role in the next stage of treatment. Based on the screening results, the items that we proposed to address complications were reserved; this finding was consistent with clinical situations. Regarding the side effects of radiochemotherapy and endocrine therapy, items including gastrointestinal reactions and hair loss were removed based on the screening results. The medical cases selected for this study involved patients who received surgery more than six months ago, these symptoms have minimal effects on the total health of the patients. Items reserved in the final version of the PRO scale addressed the side effects, including the side effects of endocrine therapy, drug-induced osteoporosis, and toxic reactions of the cardiovascular system induced by Adriamycin and other chemotherapy drugs. These side effects are long-lasting and have a significant impact on the health of the patients.

The results showed that the majority of the deleted items were derived from FACT-B. Most patients gave more attention to subjective feelings of symptoms instead of the quality of life when completing the questionnaire. According to the patients, the discomfort symptoms caused additional suffering. The results are consistent with our expectations. A PRO emphasizes subjective feelings. The focus of PRO differs from the focus of the quality of life scales and readily reflects the significance of developing PROs. The items in the PRO scale that belong to the domains of social relations and environment were also screened. The results showed that the items that address marriage, sexual life and emotions should be deleted. We believe that many patients do not provide accurate real answers due to pride or other reasons. Therefore, we should protect patients’ rights of privacy in future studies. Therefore, the scale failed to successfully evaluate the long-term therapeutic efficacy. In addition, the scale was unable to reflect dynamic changes over time. We will continue to enrich the content and improve the construction of the PRO scale to obtain better evaluations of therapeutic efficacy.

Acknowledgements

This work was supported by a grant from the Natural Science Foundation of Anhui Province (1408085QH184).

References

Arbuckle R, Abetz L, Durmer JS, et al (2010). Development of the pediatric restless legs syndrome severity scale (P-RLSSS): a patient-reported outcome measure of pediatric RLS symptoms and impact. Sleep Med, 11, 897-906.

Anthoine E, Moret L, Regnault A, et al (2014). Sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures. Health Qual Life Outcomes, 12, 176.

Cella D, Yount S, Rothrock N (2007). The patient-reported outcomes measurement information system (promis) progress of an NIH roadmap cooperative group during its first Two Years. Medical Care, 45, 3-11.

FDA (2006). Guidance for industry-patient-reported outcome measures in medical product development to support labeling claims, draft guidance. Health Qual Life, 4, 79

Fiscella K, Ransom S, Jean-Pierre P, et al (2011). Patient reported outcome measures suitable to assessment of patient navigation. Cancer, 117, 3603-17.

Kanatas A, Velikova G, Roe B, et al (2012). Patient-reported outcomes in breast oncology: a review of a validated outcome instruments. Tumori, 98, 678-88.

Luquians A, Whalley D, Crawford SR, et al (2015). Development of the alcohol quality of life scale (AQoLS): a new patient-reported outcome measure to assess health-related quality of life in alcohol use disorder. Qual Life Res, 24, 1471-81.

Mills RJ, Young CA, Pallant JF, et al (2010). Development of a patient reported outcome scale for fatigue in multiple sclerosis. The neurological fatigue index (NFI-MS). Health Qual Life Outcomes, 12, 22.

McAllister M, Wood AM, Dunn G, et al (2011). The genetic counseling outcome scale: a new patient-reported outcome measure for clinical genetics services. Clin Gener, 79, 413-24.

Ohsumi S, Shimozuma K (2013). Current status and future perspectives of patient-reported outcome research in clinical trials for patients with breast cancer in Japan. Breast Cancer, 20, 296-301.

Pusic AL, Klassen AF, Scott AM, et al (2009). Development of a new patient-reported outcome measure for breast surgery: the BREAST-Q. Plast Reconstr Surg, 124, 345-53.

Pusic AL, Cemal Y, Albornoz C, et al (2013). Quality of life among breast cancer patients with lymphedema: a systematic review of patient-reported outcome instruments and outcomes. J Cancer Surviv, 7, 83-92.

Pusic AL, Klassen AF, Scott AM, et al (2013). Development and psychometric evaluation of the FACE-Q satisfaction with appearance scale: a new patient-reported outcome instrument for facial aesthetics patients. Clin Plast Surg, 40, 249-60.

Zhao L, Chan K (2005). Patient-reported outcomes (PROs): an approach to evaluate treatment efficacy of chinese medicine or integrative medicine. CJIM, 11, 151-3.